Works matching DE "PARTIAL response continuous phase modulation"


Results: 8
    1
    2
    3

    The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.

    Published in:
    Leukemia & Lymphoma, 2017, v. 58, n. 6, p. 1358, doi. 10.1080/10428194.2016.1239259
    By:
    • Seftel, Matthew D.;
    • Kuruvilla, John;
    • Kouroukis, Tom;
    • Banerji, Versha;
    • Fraser, Graeme;
    • Crump, Michael;
    • Kumar, Rajat;
    • Chalchal, Haji I.;
    • Salim, Muhammad;
    • Laister, Rob C.;
    • Crocker, Susan;
    • Gibson, Spencer B.;
    • Toguchi, Marcia;
    • Lyons, John F.;
    • Xu, Hao;
    • Powers, Jean;
    • Sederias, Joana;
    • Seymour, Lesley;
    • Hay, Annette E.
    Publication type:
    Article
    4
    5
    6

    Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.

    Published in:
    Cancer Immunology, Immunotherapy, 2016, v. 65, n. 12, p. 1533, doi. 10.1007/s00262-016-1910-x
    By:
    • Alva, Ajjai;
    • Daniels, Gregory;
    • Wong, Michael;
    • Kaufman, Howard;
    • Morse, Michael;
    • McDermott, David;
    • Clark, Joseph;
    • Agarwala, Sanjiv;
    • Miletello, Gerald;
    • Logan, Theodore;
    • Hauke, Ralph;
    • Curti, Brendan;
    • Kirkwood, John;
    • Gonzalez, Rene;
    • Amin, Asim;
    • Fishman, Mayer;
    • Agarwal, Neeraj;
    • Lowder, James;
    • Hua, Hong;
    • Aung, Sandra
    Publication type:
    Article
    7
    8